e studied 55 patients with stage-IIB osteosarcoma around the knee with respect to the expression of matrix metalloproteinase (MMP)-9 in the surviving tumour cells in surgical resection specimens. They were followed up for a minimum of 2.5 years.
Osteosarcoma is an uncommon disease affecting three people per million each year. There have been significant advances in its treatment in the past 20 years. Effective chemotherapy and limb-salvage surgery result in cure in more than half of the patients. Attempts have been made to identify prognostic factors in order to assess outcome, and to identify those patients in whom more vigorous treatment may be justified. Percentage necrosis (> 90%) after neoadjuvant chemotherapy is one of the more reliable features, being significant for both overall and disease-free survival. A raised level of alkaline phosphatase at diagnosis has also been shown to be relevant in some studies, but not all. 1 The search for reliable prognostic indicators continues and numerous attempts have been made to find histological features of significance. Matrix metalloproteinases (MMP) are a class of matrix and basement-membrane-degrading enzymes which are important for matrix turnover. MMP-9 is important for neoangiogenesis both in normal tissues and tumours, 2, 3 and it is well known that tumours stimulate the growth of new blood vessels. Once these vessels penetrate a microscopic primary neoplasm the lesion acquires the potential to grow and become more aggressive, potentially threatening life. 4 The production of MMP-9 by tumour cells is associated with the development of metastases in laboratory rodents. 5 Metastatic lesions of osteosarcoma in children have been shown to be strongly positive for MMP-9. 6 We studied a group of patients with osteosarcoma around the knee in order to determine clinical prognostic factors and to investigate whether the expression of MMP-9 was a potentially useful marker.
Patients and Methods
A total of 55 patients with stage-IIB osteosarcoma treated in our unit was identified from the tumour registry records. There were 35 males and 20 females with a median age of 18 years (6 to 48). Follow-up data were obtained in April 1997 allowing a median follow-up period of 68 months (28 to 88). All had been treated according to the regime advocated by the current MRC osteosarcoma trial protocol; 52 had received neoadjuvant and three adjuvant chemotherapy, 46 patients had had limb-salvage surgery and nine aboveknee amputation.
In addition to clinical data, the following information was collected: the percentage of necrosis after chemotherapy, the level of alkaline phosphatase before and after the resection, the surgical margins around the resected specimens, the histological type, the mode of surgical treatment and the appearance of local recurrence or metastasis. The effect on outcome of the site of the primary tumour (distal femur versus proximal tibia), the duration of symptoms before diagnosis and the dimensions of the tumours were also studied.
Resected specimens were retrieved from 51 patients and blocks were selected for immunohistochemical studies. Formalin-fixed specimens were prepared in the standard fashion. Following low-temperature antigen retrieval, the sections were incubated with primary polyclonal antibodies (Binding Site Ltd, UK) and then diluted in Tris-buffered saline for one hour at room temperature (Table I) . Antibody binding was detected using a universal ABC detection kit (Binding Site Ltd) and sections were examined using Vector nova red chromogen and counterstained in Mayer's haemalum.
Synovium, cortical and medullary bone with growth plate and articular cartilage were used as external control tissues. MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13 were studied. All MMPs showed variable staining with chondrocytes of both the growth plate and articular cartilage, osteoblasts, osteoclasts, fibroblasts and some haemopoietic marrow cells. MMP-9 in particular showed a strong and consistent expression in osteoclasts. It has been shown that these cells express high levels of gelatinase-B both at sites of bone remodelling and during the initial migration from the perichondrium into the cartilaginous bone model before initiation of ossification. 2 Osteoclasts were therefore chosen as internal controls with MMP-9. In addition, MMP-2 and MMP-7 showed strong expression in endothelial cells. The results were assessed by an experienced pathologist, blinded as to clinical information. The immunostaining intensity in tumour cells was graded from absent (0), mild (+), moderate (++), to marked (+++), using both internal and external controls. The percentage of tumour cells stained with antibody was recorded as <25%, 25% to 50%, 50% to 75%, 75% to 90% and more than 90%.
The size of the tumour was calculated using data obtained from the initial CT and MR scans to establish the maximum dimensions of length (a), width (b), and depth (c) and the volume was calculated according to the equation: volume = [(4/3)abc]. The level of alkaline phosphatase was either normal or raised, depending upon the age-adjusted normal levels of our laboratory. For statistical analysis we used SPSS 9.0 for Windows software (SPSS Inc, Chicago, Illinois).
The importance of the prognostic factors was assessed using the log-rank test and the overall survival of patients was calculated using Kaplan-Meier survival curves. Independence of factors found significant in single variable analysis was studied using the chi-squared test. Multiple variable analysis was carried out using Cox regression models with variables chosen using forward and backward stepwise methods with deviance statistics. Significance was set at p < 0.05. The survival time for all patients was calculated from the time of diagnosis.
Results
The five-year overall survival was 47%. The median length of affected bone was 10 cm (6 to . The median length of tumour in patients requiring amputation was 9 cm whereas for those having limb-salvage surgery it was 10 cm. The median duration of symptoms before diagnosis was three months. Of the 46 patients (84%) who had salvage surgery, 12 had margins of excision measuring less than 3 mm (seven femoral; five tibial). Therefore, 34 (74%) had adequate resection of margins. The percentage of necrosis after chemotherapy was measured in 52 resected specimens; 14 (27%) had necrosis of <50%, 25 (48%) of between 50% and 90% and 13 (25%) >90%. From the 51 resection blocks all MMPs, except MMP-9, showed variable staining in chondroblastic areas and no staining in stromal tumour cells. There was positive staining for MMP-9 in 45 blocks in the tumour cells and in areas with chondroblastic differentiation; 37 were positive in the tumour cells, eight in the chondroblastic areas (Figs 1 and 2) and 11 were positive for both.
In the specimens in which tumour cells stained positively, 26 were positive in less than 25% of the cells, five in 25% to 50%, two in 50% to 70% and four in more than 75% of the tumour cells (Table II) . The number of patients does not allow statistical analysis for survival comparison to be performed between the subgroups.
There was local recurrence in nine patients at a median of 24 months and 38 patients developed metastatic disease, at a median of 15.5 months after diagnosis. Only six patients with metastatic disease were alive at the end of follow-up and 17 patients remained free from metastatic disease. MMP-9 was found to be positive in the tumour cells in only seven of these patients. Of the 38 patients who developed metastatic disease, 31 were positive for MMP-9 in the tumour cells. Ten of these tumours were positive for MMP-9 in more than 25% of the surviving tumour cells.
Single variable analysis showed that tumours positive for MMP-9 in the malignant spindle cells after chemotherapy, had significantly shorter overall survival and disease-free intervals. Patients with tumour necrosis of more than 90% after chemotherapy had better overall and disease-free survival, but the figures did not reach statistical significance. Patients with elevated alkaline phosphatase at diagnosis had significantly worse overall survival but did not have significantly worse disease-free survival (Tables III and IV and  Figs 3 and 4) . No other factor was significant for overall or disease-free survival. The MMP-9 status of the tumour cells, the level of alkaline phosphatase and the percentage of necrosis after chemotherapy were independent variables as judged by chi-squared analysis. Cox regression analysis with a forwards and backwards stepwise approach showed that only the MMP-9 status of the tumour cells had a significant effect on overall (p = 0.032) and disease-free survival (p = 0.014). Mortality and disease-free hazard are approximately five and six times greater, respectively, for those with positive expression of MMP-9 in tumour cells. No other factors showed significance (Table V) . Photomicrograph showing that in high-grade chondroblastic osteosarcoma, the chondroblasts (some multinucleated) show cytoplasm staining with MMP-9 (x200). 
Discussion
The prognosis for patients with osteosarcoma has changed since the introduction of chemotherapy in the 1970s. The long-term survival has increased from 20% in the prechemotherapy era, to between 58% and 80%. features from a large number of centres and found few reliable prognostic indicators of which the histological response to chemotherapy seemed to be the strongest. In our study, tumour necrosis greater than 90% failed marginally to reach significance for overall and disease-free survival because of the small number of patients. Our results, as in other studies, identified alkaline phosphatase as an important prognostic factor for overall survival. Tumour volume did not correlate with either overall or disease-free survival. [13] [14] [15] This is the first time that MMP-9 has been found to be a significant prognostic factor for the development of metastatic disease and the survival of patients with osteosarcoma. Our study shows that some post-chemotherapy osteosarcoma specimens express MMP-9 in the surviving tumour cells after chemotherapy. Himmelstein et al 6 found intense MMP-9 staining in most tumour cells from all biopsy samples of osteosarcomas before treatment. After chemotherapy resected samples stained similarly, but with fewer positively staining cells. Moreover, in patients who developed metastatic disease, MMP-9 was strongly expressed in four of five specimens of pulmonary metastasis. Studies on transplantable osteosarcomas suggest that overexpression of MMP-9 is one of the essential factors related to the development of metastatic disease. Restricted MMP-9 activity was associated with fewer metastatic pulmonary lesions, whereas increased activity was associated with a high metastatic potential. 16, 17 In other malignant tumours an increased expression of MMP-9 is seen in highgrade compared with low-grade, and in advanced compared with early-stage tumours. [18] [19] [20] [21] [22] [23] The expression of MMP-9 in association with angiogenic factors such as vascular endothelial growth factor has been reported in a variety of human tumours. The coexistence of these two molecules in tumours could explain why tumour vessels are leaky, predisposing to metastatic disease. [24] [25] [26] Tumour angiogenesis is associated with bad prognosis, because tumours expand and show rapid and highly significant increases in volume only after their penetration by new blood vessels. 4, 27 Neoangiogenesis is stimulated by hypoxia and most human tumours contain a significant number of hypoxic cells. Hypoxia appears to promote both local invasion and distant metastases. 28, 29 It may also induce resistance and make chemotherapy less effective. 29 Recurrence is encouraged if the surviving tumour cells can produce angiogenic factors and establish a vascular network. 30 Microscopic tumours acquire the potential to grow when they are penetrated by new blood vessels. 4 We believe that MMP-9 in the osteosarcoma cells which survive chemotherapy, contributes to recurrence because of the ability of these cells to stimulate a new vascular network. Inhibitors of MMPs have produced encouraging results by decreasing the number, size and speed of development of metastatic nodules in animals. 30, 31 Antiangiogenic treatment may help patients with a poor response to chemotherapy and who retain tumour cells in the resection specimens, positively stained for MMP-9 or other angiogenic factors. Our results suggest that the relationship between osteosarcomas and MMP-9 is worthy of further study.
